Faecal calprotectin effectively excludes inflammatory bowel disease in 789 symptomatic young adults with/without alarm symptoms: a prospective UK primary care cohort study
Alimentary Pharmacology & Therapeutics2018Vol. 47(8), pp. 1103–1116
Citations Over TimeTop 10% of 2018 papers
G Walker, Lucy Moore, Neel Heerasing, Philip Hendy, M. H. Perry, Timothy J. McDonald, T. Debenham, Rob Bethune, Claire Bewshea, Christopher Hyde, Graham Heap, Arshdeep Singh, C. C. Calvert, Nicholas A. Kennedy, James Goodhand, Tariq Ahmad
Abstract
Calprotectin testing of young adults with suspected IBD in primary care accurately distinguishes IBD from functional gut disorder, even in patients with gastrointestinal alarm symptoms and reduces secondary care referrals and diagnostic healthcare costs.
Related Papers
- → Calprotectin instability may lead to undertreatment in children with IBD(2019)35 cited
- → High negative predictive value of a normal faecal calprotectin in patients with symptomatic intestinal disease(2011)17 cited
- → Faecal calprotectin—a useful screening test for detecting gastrointestinal inflammation in children(2010)
- → Letter: faecal calprotectin for the prediction of relapse in inactive inflammatory bowel disease – authors’ reply(2016)
- → P06 A single centre description of IBD patients with negative faecal calprotectin at diagnosis(2021)